证券日报网讯 7月30日晚间，汇宇制药发布公告称，公司全资子公司四川汇宇海玥医药科技有限公司自 主研发的1类生物创新药注射用HY0001a（项目研发代号为"HY-0001"）正在开展用于治疗晚期实体瘤的 Ⅰ期临床试验，于近日成功完成首例受试者给药。 （文章来源：证券日报） ...

每经AI快讯，7月30日，汇宇制药(688553.SH)公告称，公司全资子公司汇宇海玥自主研发的1类生物创 新药注射用HY0001a用于治疗晚期实体瘤的I期临床试验近日成功完成首例受试者给药。该产品为抗体 偶联药物，注册分类为1类创新型治疗用生物制品，国内外尚无同靶点产品获批上市。 ...

Core Viewpoint - Huiyu Pharmaceutical's subsidiary Huiyu Haiyue has received approval from the National Medical Products Administration for clinical trials of its innovative drug HY0001a, aimed at treating advanced solid tumors, marking a significant milestone in the company's research and development efforts [1] Group 1 - The clinical trial approval is for the injectable HY0001a, which is an antibody-drug conjugate developed independently by the company [1] - HY0001a is classified as a Class 1 innovative therapeutic biological product [1] - As of the announcement date, there are no approved products targeting the same site in both domestic and international markets, making this the first drug globally to enter clinical trials for this target [1]

汇宇制药公告，全资子公司汇宇海玥收到国家药品监督管理局核准签发的《受理通知书》，注射用 HY0001a用于治疗晚期实体瘤的临床试验申请获得受理。注射用HY0001a为全球首个披露针对该靶点推 向临床的药物，国内外尚无同靶点产品获批上市。 ...